Psychedelic Startups, Biotech, Drug Discovery, Psilocybin, DMT, Psychedelics & Society | Sam Banister | 79
Mind & Matter
00:00
Silosiben
We're not doing silis ibon, or any natural psychelix as such. We are looking at using a number of innovative a medicinal chemistry approaches to actually modifying first generation psychodelics in a more dramatic way. Our hypothesis here is that we'll get different target receptory engagements, which we've already demonstrated for a number of these compounds, and that that will lead to a different benefits in the clinic.
Play episode from 07:32
Transcript
